Lead Product(s) : Bimiralisib
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Torqur AG Presents Interim Phase 2 Clinical Trial Results
Details : Bimiralisib is a selective pan-PI3K/mTOR inhibitor, which is being evaluated for the topical treatment of actinic keratosis of the face or scalp.
Product Name : PQR309
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 07, 2025
Lead Product(s) : Bimiralisib
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
MoonLake Receives Positive Feedback On Sonelokimab Phase 3 Program
Details : M1095 (sonelokimab) is a humanized Nanobody® being evaluated for hidradenitis suppurativa treatment, consisting of three VHH domains linked by flexible spacers.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
February 26, 2024
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : M1095 (sonelokimab) is a humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with IL-17A and IL-17F and inhibit IL-17A/A, IL-17A/F, and IL-17F/F dimer, which investigated for moder...
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
October 15, 2023
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab,Adalimumab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : SVB Securities
Deal Size : $400.0 million
Deal Type : Public Offering
Details : MoonLake intends to use the net proceeds to fund the ongoing advancement of M1095 (sonelokimab), a trivalent monomeric nanobody that neutralizes interleukins IL-17A, IL-17F, and IL-17A/F for the treatment of inflammatory diseases.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Undisclosed
June 28, 2023
Lead Product(s) : Sonelokimab,Adalimumab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : SVB Securities
Deal Size : $400.0 million
Deal Type : Public Offering
Lead Product(s) : Sonelokimab,Adalimumab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : M1095 (sonelokimab) is a humanized nanobody consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with IL-17A and IL-17F and inhibit IL-17A/A, IL-17A/F, and IL-17F/F dimer, which investigated for hidra...
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
June 25, 2023
Lead Product(s) : Sonelokimab,Adalimumab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : M1095 (sonelokimab) is a humanized nanobody® consisting of three VHH domains covalently linked by flexible glycine-serine spacers. It selectively binds with high affinity to IL-17A and IL-17F and inhibits IL-17A/A, IL-17A/F, and IL-17F/F dimers.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
February 02, 2023
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : M1095 (sonelokimab) inhibits the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation. In addition, sonelokimab is designed to directly target sites of inflammation and penetrate difficult-to-reach inflamed tissues.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Inapplicable
December 05, 2022
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Vetter Pharma-Fertigung GmbH & Co
Deal Size : Undisclosed
Deal Type : Agreement
Details : Sonelokimab (M1095), is MoonLake’s investigational Nanobody® designed to treat inflammatory disease by inhibiting the naturally occurring IL-17A/A, IL-17A/F, and IL-17F/F dimers that drive inflammation.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Undisclosed
July 26, 2022
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Vetter Pharma-Fertigung GmbH & Co
Deal Size : Undisclosed
Deal Type : Agreement
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Helix BioPharma
Deal Size : Undisclosed
Deal Type : Termination
Details : MoonLake plans to execute on its development program to unlock the potential of Sonelokimab, the novel investigational Nanobody® for the treatment of inflammation, to revolutionize outcomes for patients with inflammatory diseases.
Product Name : M1095
Product Type : Antibody
Upfront Cash : Undisclosed
May 04, 2022
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Helix BioPharma
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Study Phase : Phase II
Sponsor : Helix BioPharma
Deal Size : Undisclosed
Deal Type : Agreement
Details : Proceeds from the transaction are expected to provide MoonLake with the capital needed to accelerate the development of the clinical stage, tri-specific Nanobody® sonelokimab, in multiple inflammatory diseases in dermatology and rheumatology driven by I...
Product Name : M1095
Product Type : Antibody
Upfront Cash : $230.0 million
April 10, 2021
Lead Product(s) : Sonelokimab
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Sponsor : Helix BioPharma
Deal Size : Undisclosed
Deal Type : Agreement